Overactive Bladder Treatment Market Analysis by Therapy (Anticholinergics, Mirabegron, Neurostimulation, and Intravesical Instillation); and by Disease Type (Idiopathic Overactive Bladder, and Neurogenic Overactive Bladder) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now Report ID: 4868 | Published Date: Apr 30, 2023
Overactive Bladder Treatment Market size is estimated to reach ~USD 9.73 Billion by the end of 2035 by growing at a CAGR of ~6.60% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of over active bladder treatment was ~USD 4.52 Billion. The growth of the market can be attributed to growing prevalence of overactive bladder. However, where overactive bladder is commonly seen in older people, their prevalence is also high in younger individuals. Up to 32 million persons in the U.S., including up to about 29% of men and approximately 39% of women, were having overactive bladder in 2022. Hence, the demand for overactive bladder treatment is growing.
Moreover, surge in prevalence of urinary tract infections (UTIs) is also driving demand for overactive bladder treatment. A UTI would occur in roughly 19% of (assigned female at birth) AFAB individuals at some time in their lives. UTIs may harm men and those who were assigned male at birth (AMAB), however they only affect about 2% of children. Every year, approximately 7 million to about 11 million UTI cases are treated by healthcare professionals in US. Hence, the demand for overactive bladder treatment is growing since overactive bladder symptoms are frequently caused by urinary tract infections (UTIs) in persons of all ages, including young adults.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~6.60% |
|
Base Year Market Size (2022) |
~ USD 4.52 Billion |
|
Forecast Year Market Size (2035) |
~ USD 9.73 Billion |
|
Regional Scope |
|
Growth Drivers
Challenges
The global industry is segmented and analyzed for demand and supply by disease type into idiopathic overactive bladder, and neurogenic overactive bladder. Out of which, the idiopathic overactive bladder segment is anticipated to garner the highest revenue by the end of 2035. Overactive bladder (OAB) caused by idiopathic causes is more common than OAB caused by neurogenic causes. Idiopathic OAB describes OAB symptoms for which there is no known underlying cause such as found in obesity. Hence, the growth of the segment can be attributed to growing prevalence of obesity which further cause abnormalities in the bladder muscle or nerves. Around the world, 650 million adults, 340 million teenagers, and 39 million children are obese. This quantity is still rising. By 2025, the WHO predicts that 167 million adults and children would lose some of their health simply from being overweight or obese. Since, OAB symptoms including urge incontinence, frequency, and urine urgency could be effectively decreased or eliminated with OAB treatment, it is often used to treat idiopathic OAB. Some instances of lifestyle changes that may improve bladder control and lessen OAB symptoms include bladder training and pelvic floor exercises. Beta-3 agonists and antimuscarinic medications, for instance, may reduce bladder tension and lessen frequent and urgent urination.
The global overactive bladder treatment market is also segmented and analyzed for demand and supply by therapy into anticholinergics, mirabegron, neurostimulation, and intravesical instillation. Amongst which, the neurostimulation segment is expected to have the significant growth over the forecast period. Overactive bladder (OAB) may be treated with neurostimulation, which uses an implantable device to stimulate the sacral nerves. This has the potential to control bladder function and lessen OAB symptoms including frequent and urgent urination. Moreover, neurostimulation is typically performed as an outpatient procedure and is comparatively non-invasive when compared to surgery or other invasive procedures. Additionally, compared to medicine, which could result in constipation, dry mouth, and other side effects, neurostimulation has less systemic side effects.
Our in-depth analysis of the global overactive bladder treatment market includes the following segments:
|
By Therapy |
|
|
By Disease Type |
|
The market share of overactive bladder treatment in North America, amongst the market in all the other regions, is projected to have the highest growth by the end of 2035, backed by growing geriatric population along with increased awareness among people. The percentage of older Americans is expected to grow from 15% to 21% by 2030, when all baby boomers are projected to be above the age of 65. Nearly one in four Americans would be 65 or older by 2060, tripling the number of those who are 85 or older, and a half million more would be centenarians. Moreover, many people in North America lead sedentary lifestyles, spending lengthy periods of time at desks or in front of computers. OAB symptoms might be exacerbated by inactivity, which raises the need for treatment. Additionally, North America has a highly accessible healthcare system with a well-developed healthcare infrastructure. This makes it simpler for people with OAB to get the care they need and the tools they require to manage their illness.
The Asia Pacific overactive bladder treatment market is estimated to be the second largest, to have the highest growth over the forecast period. The prevalence of chronic conditions including diabetes, obesity, and cardiovascular disease has increased throughout the Asia Pacific area, which raises the chance of acquiring OAB treatment. Additionally, a rising middle class in the Asia Pacific area has widened access to healthcare facilities and improved people's ability to pay for OAB treatment. Further, more people are residing in cities in many of the Asia Pacific region's countries. Urbanization may worsen OAB symptoms including stress and urgency, which could increase the need for therapy.
Additionally, the overactive bladder treatment market in Europe region is also estimated to have the significant growth over the forecast period. Many European countries have universal healthcare coverage, which has improved access to healthcare and raised demand for OAB treatment. Moreover, OAB may be treated in Europe using a range of approaches, including drugs, neuromodulator therapy, and minimally invasive & non-invasive imaging and visualization system. The fact that these treatments are accessible has helped to meet the region's rising need for OAB care. Additionally, the prevalence of OAB symptoms is rising among working adults in Europe as more people stay in the employment for longer periods of time. To help people manage their symptoms and keep up their productivity at work, this has raised demand for OAB treatment. Hence, with this the market for overactive bladder is estimated to grow in this region.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The major factors driving the growth of the market are growing number of pregnancy, rise in adoption of sedentary lifestyle, surge in healthcare expenditure, and others.
Ans: The market size of overactive bladder treatment is anticipated to attain a CAGR of ~6.60% over the forecast period, i.e., 2023 – 2035.
Ans: Limited patient awareness, side effect of medication, and high cost of treatment are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Astellas Pharma, Inc., Pfizer, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and more.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by therapy, disease type, and by region.
Ans: The Idiopathic overactive bladder segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
